Robertson Stephens Wealth Management, LLC Acelrx Pharmaceuticals Inc Transaction History

Robertson Stephens Wealth Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.49 - $1.02 $65,581 - $136,516	-133,840 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$0.93 - $1.51 $82,564 - $134,056	-88,779 Reduced 39.88%	133,840 $136,000
Q2 2021 Aug 17, 2021	BUY	$1.03 - $1.7 $10,692 - $17,647	10,381 Added 4.89%	222,619 $307,000
Q1 2021 May 07, 2021	BUY	$1.25 - $2.77 $232 - $515	186 Added 0.09%	212,238 $360,000
Q3 2020 Nov 10, 2020	BUY	$1.01 - $1.81 $111,187 - $199,257	110,087 Added 107.97%	212,052 $301,000
Q2 2020 Aug 12, 2020	SELL	$1.03 - $1.69 $2,914 - $4,782	-2,830 Reduced 2.7%	101,965 $123,000
Q1 2020 May 01, 2020	BUY	$0.76 - $2.07 $79,644 - $216,925	104,795 New	104,795 $124,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Robertson Stephens Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Robertson Stephens Wealth Management, LLC with notifications on news.